Moderna Slashes 2025 Forecast, Stock Sinks 20%
Moderna has lowered its 2025 revenue outlook from an estimated $2.5–$3.5 billion to just $1.5–$2.5 billion, citing hurdles like increased Covid competition and dwindling vaccination rates. This sharp shift sent the biotech’s stock plunging 20% on Monday, with some analysts saying the company had set higher ambitions than the market could sustain.
The new numbers underscore how rapidly Moderna’s fortunes changed after its Covid vaccine boom. CFO Jamey Mock highlighted growing market obstacles, including rival shots and slower vaccine uptake, as key factors in the revised forecast. However, the company plans to offset the drop by cutting cash costs—about $1 billion in 2025, plus another $500 million in 2026.
Despite the setback, Moderna remains optimistic. It still has a pipeline packed with fresh vaccine ideas—like next-generation Covid and RSV shots—that leaders hope will gain traction and ultimately expand revenue streams. These new products could play a pivotal role in restoring investor confidence if they deliver on their promise.
For now, the steep cut in sales expectations stands as a reminder that pandemic-driven momentum can fade as market conditions evolve. Investors and industry watchers alike are keeping a close eye on Moderna’s next moves, as the company pursues bigger goals in an increasingly competitive vaccine landscape.
Disclosure: This list is intended as an informational resource and is based on independent research and publicly available information. It does not imply that these businesses are the absolute best in their category. Learn more here.
This article may contain commission-based affiliate links or sponsored content. Learn more on our Privacy Policy page.
